Simona Bianconi, 1. Department of Pediatrics, New York Methodist Hospital, Brooklyn, NY, USA
1 Madhu Gudavalli, 2. Department of Pediatrics, New York Methodist Hospital, Brooklyn, NY, USA
2 Vesna G. Sutija, 3. Department of Pediatrics, New York Methodist Hospital, Brooklyn, NY, USA
3 Anna L. Lopez, 4. International Vaccine Institute, SNU Research Park San 4-8 Bongcheon 7-dong, Kwanak-gu, Seoul 151-818, Korea
4 Lillian Barillas-Arias, 5. Department of Pediatrics, NY Presbyterian Weill Cornell Medical Center, New York, NY, USA
5 Nitin Ron6. Department of Pediatrics, New York Methodist Hospital, Brooklyn, NY, USA
6 Corresponding author: Madhu Gudavalli, MD Department of Pediatrics 506 Sixth Street Brooklyn, NY 11215, USA Tel: +1-718-780-5260
Citation Information. Journal of Perinatal Medicine. Volume 35, Issue 2, Pages 147–150, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: 10.1515/JPM.2007.017, 01/04/2007
Published Online: 07/03/2007
Abstract
Aims: The objective of the study was to examine the effect of ranitidine on the incidence of late onset sepsis.
Methods: This study was based on information extracted from charts of 569 infants admitted to the neonatal intensive care unit (NICU) from July 2003 to July 2005. All infants admitted for seven or more days were included. Late-onset neonatal sepsis was defined as a positive blood culture with clinical signs of sepsis after seven days of life. Outcome measures included the use of ranitidine, type of infection and infectious agent, birth weight gestational age, and type of care in the NICU.
Results: Of the 569 infants admitted, 53 (9.3%) were treated with ranitidine. Of 74 infants who developed late-onset sepsis, 23 infants received ranitidine and 51 did not. Infants receiving ranitidine were at 7-times greater risk of late-onset sepsis (OR 6.99; 95% CI: 3.78–12.94; P<0.0001). The birth weights and gestational ages of infants with sepsis receiving ranitidine and those not receiving ranitidine were comparable, P=0.59.
Conclusion: The use of ranitidine in infants admitted to the NICU elevates the risk of late-onset sepsis. The pathological mechanisms need to be further studied. The safety of widespread use of ranitidine in neonates is controversial.
Keywords Bacteremia, histamine 2 antagonist, neonatal intensive care unit, nosocomial infections, premature infant, ranitidine, sepsis
